Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

This is an open-label, multicenter, phase 2, non-randomized study aiming to study the efficacy and safety of fixed-duration venetoclax consolidation in CLL patients who are on BTK inhibitor monotherapy. Patients who are on BTK inhibitor monotherapy for ≥ 6 months and still responsive are included. The study includes patients who are treatment-naive before taking BTK inhibitors. Patients will be treated with the BTK inhibitor plus full-dose venetoclax for 12 cycles after a standard 5-week dose ramp-up. Peripheral blood and bone marrow MRD status will be evaluated during and after the treatment.

Trial Details

NCT ID
NCT06958705
Phase
PHASE2
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
RECRUITING
Cancer Type
Chronic Lymphocytic (CLL) Leukemia
Interventions
  • Venetoclax combined with Ibrutinib
  • Venetoclax combined with Zanubrutinib
  • Venetoclax combined with Acalabrutinib
  • Venetoclax combined with Orelabrutinib
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • 1\. Age: 18-80 years-old.
  • 2\. Patients must have a diagnosis of CLL/SLL.
  • 3\. Detectable MRD by flow cytometry (10\^-4 sensitivity) in the peripheral blood.
  • 4\. Patients who are on BTK inhibitor monotherapy for more than 6 months. This study includes patients who are taking one of the following BTK inhi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Chronic Lymphocytic (CLL) Leukemia Trials on Trialify →